Sign In
Buy PHAT
$10.09
+0.440 (+4.56%)
At Close: Jun 03, 2026
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
10:20am, Thursday, 07'th Nov 2024
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Monday, 04'th Nov 2024
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
08:00am, Monday, 28'th Oct 2024
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
12:00pm, Sunday, 27'th Oct 2024
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary du
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Thursday, 29'th Aug 2024
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
08:00am, Monday, 19'th Aug 2024
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
02:52pm, Saturday, 10'th Aug 2024
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CE
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
10:21am, Thursday, 08'th Aug 2024
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago.
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
08:00am, Thursday, 08'th Aug 2024
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a signifi
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
06:11am, Wednesday, 26'th Jun 2024
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its produ
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
06:17am, Friday, 07'th Jun 2024
One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 28'th May 2024
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
07:03pm, Saturday, 11'th May 2024
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief E
